Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Servier, MacroGenics Forge Option Deal For Cancer Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

The French pharma acquires the right to license the antibody MGA271, which has received strong interest since BMS’s Yervoy was approved in March.

You may also be interested in...



MacroGenics Strikes Second Oncology Partnership With Servier

The French pharma paid $20 million up-front for rights to option three preclinical programs, including drugs targeting both solid and liquid-tumor cancers.

Yervoy Approval Has Shifted Development Landscape For Melanoma

With Bristol-Myers Squibb Co.’s ipilimumab cleared and Roche/Daiichi Sankyo’s BRAF inhibitor vemurafenib (RG7204) on track for a filing and perhaps approval this year, companies developing other melanoma drugs face a more complicated, competitive path to market.

Pfizer, Boehringer Ingelheim Tap MacroGenics In Separate Deals

The startup strikes a two-drug oncology deal with Pfizer and a ten-target agreement with BI just days after Lilly halted development of its lead compound.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS073108

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel